AMGN Amgen Inc.
Research report · from SEC EDGAR
executive summary
Amgen Inc. (AMGN). Revenue is $36.75B (+10.0% y/y) at a 21% net margin. It is profitable. Our health score is B (80/100). No major red flags on file. Smart money is buying (1 Congress, 1 funds). It funds itself; low dilution risk.
Revenue (FY)
$36.75B
+10.0% y/y
✓ No major red flags from our filing-based checks.
who's buying
Insider buys / sells
0 / 0
Cash & ST investments
$12.04B
Operating cash flow
$9.96B
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated today by stocktools.ai.